Gout - Pipeline Review, Q4 2010


December 8, 2010
50 Pages - SKU: GMD6045726
License type:
Table of Contents Search inside this report Related Reports
Introduction
Global Markets Direct Report Coverage
Gout Overview
Therapeutics Development
An Overview of Pipeline Products for Gout
Gout Therapeutics under Development by Companies
Gout Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Gout Therapeutics Development
Addex Pharmaceuticals
Ardea Biosciences, Inc.
BioCryst Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
XOMA Ltd.
Metabolex, Inc
Wellstat Therapeutics Corporation
PLx Pharma Inc.
EnzymeRx, Inc.
Allostera Pharma Inc.
Nuon Therapeutics, Inc.
Universities/Institutes Involved in Gout Therapeutics Development
Gout Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles - Companies
Arcalyst - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arcalyst + Indomethacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles - Universities/Institutes
Zoledronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Gout - Featured News
Nov 08, 2010: BioCryst To Present New Data For BCX4208 Monotherapy At 74th Annual American College Of Rheumatology Scientific Meeting
Sep 29, 2010: Nuon Therapeutics To Present Gout Program Study Results At American College Of Rheumatology Meeting 2010
Sep 16, 2010: BioCryst Reports Positive Results From A Phase II Study Of BCX4208 Combined With Allopurinol In Patients With Gout
Sep 16, 2010: BioCryst Announces Positive Phase II Study Results Of BCX4208 Combined With Allopurinol In Patients With Gout
Jun 18, 2010: Novartis Reports New Data From Phase II Study Of ACZ885 In Gout Patients
Jun 18, 2010: Ardea Presents Positive Phase II Data On RDEA594 For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Interim Results From Phase Ib Study Of RDEA594 In Combination With Allopurinol For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Data From Proof-Of-Concept Study Examining Combination Of RDEA594 And Febuxostat For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 09, 2010: Arcalyst (rilonacept) Meets Primary And All Secondary Endpoints In Phase 3 Trial Of Prevention Of Gout Flares In Patients Initiating Allopurinol Therapy
Jun 09, 2010: Regeneron Pharmaceuticals Announces That ARCALYST (rilonacept) Meets Primary And All Secondary Endpoints In Phase III Trial Of Prevention Of Gout Flares In Patients Initiating Allopurinol Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Gout, 2010
Products under Development for Gout - Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
Addex Pharmaceuticals, 2010
Ardea Biosciences, Inc., 2010
BioCryst Pharmaceuticals, Inc., 2010
Regeneron Pharmaceuticals, Inc., 2010
XOMA Ltd., 2010
Metabolex, Inc, 2010
Wellstat Therapeutics Corporation, 2010
PLx Pharma Inc., 2010
EnzymeRx, Inc., 2010
Allostera Pharma Inc., 2010
Nuon Therapeutics, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products
List of Figures
Number of Products under Development for Gout, 2010
Products under Development for Gout - Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Discovery and Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Rheumatology/Arthritis Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!